Gene-targeted therapies: Towards equitable development, diagnosis, and access

Area of Science:

• Genetics
• Medical Ethics
• Health Equity

Background:

• Rare diseases affect a significant global population, necessitating innovative therapeutic approaches.
• Genomic and gene-targeted therapies represent a promising frontier for treating rare genetic disorders.
• Existing disparities in healthcare access pose a significant barrier to realizing the full potential of these advanced therapies.

Purpose of the Study:

• To emphasize the critical need for health equity in the development and accessibility of genomic and gene-targeted therapies for rare diseases.
• To highlight the importance of considering ethical, legal, and social implications from the outset of research and therapeutic development.
• To underscore the necessity of addressing access to both diagnosis and treatment for individuals with rare diseases.

Main Methods:

• This article presents a discussion and synthesis of current challenges and considerations in rare disease research and care.
• It reviews the intersection of genomic medicine, therapeutic development, and health equity frameworks.
• Ethical, legal, and social implications (ELSI) are examined in the context of research translation and clinical implementation.

Main Results:

• Equitable access to rare disease testing, diagnosis, and gene-targeted therapies is a fundamental requirement for realizing their promise.
• Innovations in research, clinical practice, regulatory pathways, and reimbursement are essential for achieving equity.
• Proactive attention to ethical, legal, and social issues is paramount for successful translation of research into accessible interventions.

Conclusions:

• Health equity must be a central consideration throughout the entire lifecycle of rare disease research and therapy development.
• Addressing disparities in access to genomic medicine is crucial for ensuring that advancements benefit all populations affected by rare diseases.
• A multi-faceted approach integrating scientific, ethical, and societal considerations is required to achieve equitable outcomes in rare disease care.